Aqr Capital Management LLC Savara Inc Transaction History

Aqr Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $17,234 - $25,146	-4,709 Reduced 22.22%	16,483 $66,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $23,007 - $30,694	5,491 Added 34.97%	21,192 $105,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $49,929 - $76,934	15,701 New	15,701 $73,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $34,822 - $48,398	-29,511 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $44,561 - $67,580	29,511 New	29,511 $50,000
Q2 2019 Aug 14, 2019	SELL	$2.37 - $11.7 $35,509 - $175,301	-14,983 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$6.71 - $8.6 $21,055 - $26,986	-3,138 Reduced 17.32%	14,983 $110,000
Q3 2018 Nov 15, 2018	BUY	$10.49 - $12.87 $14,088 - $17,284	1,343 Added 8.0%	18,121 $202,000
Q2 2018 Aug 14, 2018	BUY	$8.55 - $13.76 $143,451 - $230,865	16,778 New	16,778 $190,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.